0000000000330718

AUTHOR

Peter J. Barnes

showing 6 related works from this author

Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD

2009

BACKGROUND: Increased numbers of activated neutrophils have been reported in the bronchial mucosa of patients with stable chronic obstructive pulmonary disease (COPD), particularly in severe disease. OBJECTIVES: To investigate the expression of neutrophilic chemokines and adhesion molecules in bronchial biopsies from patients with stable COPD of different severity (GOLD stages I-IV) compared with age-matched control subjects, smokers with normal lung function and never smokers. METHODS: The expression of CCL5, CXCL1, 5, 6, 7 and 8, CXCR1, CXCR2, CD11b and CD44 was measured in the bronchial mucosa using immunohistochemistry, confocal immunofluorescence, real-time quantitative polymerase chai…

MalePulmonary and Respiratory MedicineChemokinePathologymedicine.medical_specialtyCOPD neutrophils bronchial mucosa CCL5 CXCL7BronchiRespiratory MucosaGranulocyteNeutrophil ActivationCCL5Pulmonary Disease Chronic ObstructiveneutrophilsSubmucosaCOPDHumansMedicineCXC chemokine receptorsChemokine CCL5AgedCOPDbronchial mucosaCCL5biologySettore BIO/16 - Anatomia UmanaCD11 Antigensbusiness.industryCD44Epithelial CellsMiddle Agedrespiratory systemmedicine.diseaseRespiratory Function Testsrespiratory tract diseasesCXCL1Hyaluronan Receptorsmedicine.anatomical_structureAcute DiseaseImmunologyCXCL7biology.proteinFemaleLeukocyte ElastasebusinessCOPD; neutrophils; bronchial mucosa; CCL5; CXCL7Chemokines CXCCOPD CCL5CXCL7NEUTROPHILThorax
researchProduct

Alternative mechanisms for tiotropium

2009

Tiotropium is commonly used in the treatment of chronic obstructive pulmonary disease. Although largely considered to be a long-acting bronchodilator, its demonstrated efficacy in reducing the frequency of exacerbations and preliminary evidence from early studies indicating that it might slow the rate of decline in lung function suggested mechanisms of action in addition to simple bronchodilation. This hypothesis was examined in the recently published UPLIFT study and, although spirometric and other clinical benefits of tiotropium treatment extended to four years, the rate of decline in lung function did not appear to be reduced by the addition of tiotropium in this study. This article summ…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyANTICHOLINERGIC BRONCHODILATORmedicine.drug_classRespiratory SystemScopolamine DerivativesPulmonary diseaseIPRATROPIUM BROMIDEIpratropium bromideOBSTRUCTIVE PULMONARY-DISEASEMUCOCILIARY CLEARANCECholinergic AntagonistsRECEPTORS MEDIATE STIMULATIONParasympathetic Nervous SystemAIRWAY SMOOTH-MUSCLEBronchodilatorBronchodilationMechanismsBRONCHIAL EPITHELIAL-CELLSAnimalsHumansMedicineCOPDPharmacology (medical)Tiotropium BromideIntensive care medicineLungLung functionInflammationCOPDbusiness.industryTiotropiumBiochemistry (medical)RemodellingTiotropium bromidemedicine.diseaseAcetylcholineBronchodilator Agentsrespiratory tract diseasesMucusClinical researchNONNEURONAL CHOLINERGIC SYSTEMCoughPOLYSPECIFIC CATION TRANSPORTERSAnesthesiaLUNG FIBROBLAST PROLIFERATIONbusinesshuman activitiesmedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression.

2017

Toll-like receptors (TLRs) and nucleotide-binding oligomerisation domain (NOD)-like receptors (NLRs) are two major forms of innate immune sensors but their role in the immunopathology of stable chronic obstructive pulmonary disease (COPD) is incompletely studied. Our objective here was to investigate TLR and NLR signalling pathways in the bronchial mucosa in stable COPD.Using immunohistochemistry, the expression levels of TLR2, TLR4, TLR9, NOD1, NOD2, CD14, myeloid differentiation primary response gene 88 (MyD88), Toll-interleukin-1 receptor domain-containing adaptor protein (TIRAP), and the interleukin-1 receptor-associated kinases phospho-IRAK1 and IRAK4 were measured in the bronchial muc…

0301 basic medicineTIRAPMaleRespiratory SystemVital CapacityHAEMOPHILUS-INFLUENZAELUNG MICROBIOMEPathogenesisPulmonary Disease Chronic Obstructive0302 clinical medicineNOD2ImmunopathologyForced Expiratory VolumeNod1 Signaling Adaptor ProteinNOD1PhosphorylationCOPDSmoking11 Medical And Health SciencesMiddle AgedCPG-DNAbronchial inflammationAnti-Bacterial AgentsStreptococcus pneumoniaePseudomonas aeruginosaMOUSE LUNGFemaleLife Sciences & BiomedicineMoraxella catarrhalisSignal TransductionEXPRESSIONPulmonary and Respiratory MedicineCD14BronchiRespiratory MucosaReal-Time Polymerase Chain ReactionOBSTRUCTIVE PULMONARY-DISEASETLRs NLR bronchial inflammationNLRDENDRITIC CELL SUBSETS03 medical and health sciencesProtein DomainsmedicineHumansTLRsAgedTOLL-LIKE RECEPTORSCOPD TLR4InflammationScience & TechnologyBacteriabusiness.industrymedicine.diseaseHaemophilus influenzaeBacterial Loadrespiratory tract diseasesToll-Like Receptor 4TLR2030104 developmental biology030228 respiratory systemImmunologyINNATE IMMUNITYT-CELLSbusinessThe European respiratory journal
researchProduct

The hidden burden of severe asthma: from patient perspective to new opportunities for clinicians

2020

Severe asthma is an important topic in respiratory diseases, due to its high impact on morbidity and mortality as well as on health-care resources. The many challenges that still exist in the management of the most difficult-to-treat forms of the disease, and the acknowledgement of the existence of unexplored areas in the pathophysiological mechanisms and the therapeutic targets represent an opportunity to gather experts in the field with the immediate goals to summarize current understanding about the natural history of severe asthma and to identify gaps in knowledge and research opportunities, with the aim to contribute to improved medical care and health outcomes. This article is a conse…

severe asthmamedicine.medical_specialtySevere asthmaprecision medicineAcknowledgementlcsh:MedicineSocio-culturaleReviewDiseasebiomarkers patient’s perspective precision medicine severe asthma.Medical care03 medical and health sciencesTherapeutic approach0302 clinical medicineMedicine030212 general & internal medicineddc:610Intensive care medicinebusiness.industrylcsh:RPerspective (graphical)General MedicineResearch opportunitiesBiomarkers patient’s perspective precision medicine severe asthmaBiomarkers; Patient’s perspective; Precision medicine; Severe asthmapatient’s perspectiveNatural history030228 respiratory systembusinessBiomarkers
researchProduct

The relationship between age and production of tumour necrosis factor-α in healthy volunteers and patients with chronic heart failure

2003

Ageing is associated with an altered immune response. Elevated plasma levels of tumour necrosis factor-alpha (TNF-alpha) are present in patients with advanced chronic heart failure (CHF). However, the relationship between age and the immune response in CHF is unknown.We investigated the relationship between age and the TNF-alpha generating capacity of lipopolysaccharide (LPS) stimulated peripheral blood mononuclear cells (PBMC) in nine healthy control subjects (mean age 51.6+/-3.6 years, age range 39-75 years) and 22 stable patients with CHF (mean age 68.3+/-1.5 years, age range 52-78 years, NYHA class 3.0+/-0.2). We also tested the TNF-alpha generating capacity of all control subjects and …

AdultLipopolysaccharidesMalemedicine.medical_specialtyHeart diseaseEnzyme-Linked Immunosorbent AssayPeripheral blood mononuclear cellMonocytesImmune systemInternal medicinemedicineHumansAgedWhole bloodHeart FailureAnalysis of VarianceTumor Necrosis Factor-alphabusiness.industryAge FactorsGestational ageMiddle Agedmedicine.diseaseLogistic ModelsEndocrinologyAgeingCase-Control StudiesHeart failureChronic DiseaseImmunologyFemaleTumor necrosis factor alphaCardiology and Cardiovascular MedicinebusinessBiomarkersInternational Journal of Cardiology
researchProduct

T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients.

2009

Summary There are increased numbers of activated T lymphocytes in the bronchial mucosa of stable chronic obstructive pulmonary disease (COPD) patients. T helper type 17 (Th17) cells release interleukin (IL)-17 as their effector cytokine under the control of IL-22 and IL-23. Furthermore, Th17 numbers are increased in some chronic inflammatory conditions. To investigate the expression of interleukin (IL)-17A, IL-17F, IL-21, IL-22 and IL-23 and of retinoic orphan receptor RORC2, a marker of Th17 cells, in bronchial biopsies from patients with stable COPD of different severity compared with age-matched control subjects. The expression of IL-17A, IL-17F, IL-21, IL-22, IL-23 and RORC2 was measure…

MaleTranslational StudiesReceptors Retinoic Acidmedicine.medical_treatmentImmunologyautoimmunity bronchial biopsies emphysema neutrophilsInflammationBronchiInterleukin-23Polymerase Chain ReactionStatistics NonparametricPulmonary Disease Chronic ObstructiveAutoimmunity bronchial biopsies emphysema neutrophils pathologymedicineInterleukin 23Immunology and AllergyHumansRNA MessengerAgedDNA PrimersCOPDAnalysis of VarianceMucous MembraneReceptors Thyroid Hormonebusiness.industryInterleukinsRespiratory diseaseInterleukin-17SmokingInterleukinT-Lymphocytes Helper-InducerMiddle AgedNuclear Receptor Subfamily 1 Group F Member 3medicine.diseaseImmunohistochemistryrespiratory tract diseasesRespiratory Function TestsCytokineCase-Control StudiesImmunologyFemaleInterleukin 17medicine.symptombusinessCD8
researchProduct